



NDA Announcement

[April 11, 2018] – Innocoll announces that it has received acceptance of its resubmission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for XARACOLL. The Prescription Drug User Fee Act (“PDUFA”) date is 2 December 2018. As with all NDAs, there is no guarantee of approval, but the acceptance provides a path for possible approval later this year and product launch in early 2019.

Innocoll makes this announcement notwithstanding the fact that it has no public disclosure obligations as an unlisted, private company.